Project Grant H3048960

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,250,837 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to develop a gene editing approach using lipid nanoparticles (LNPs) and CRISPR/Cas9 tools to permanently correct the mutated Factor VIII (FVIII) gene and restore FVIII expression for the treatment of hemophilia A. The project aims to enhance LSEC-targeting of LNPs and...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,435,366 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Oregon Health & Science University. The grant, titled "Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study," will conduct a multicenter clinical trial to evaluate the effectiveness of progestin treatments in managing heavy menstrual bleeding and improving quality of life for adolescents and young adults...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $169,156 to The Washington University in St. Louis to support a 5-year research program focused on optimizing hematopoietic stem cell transplantation (HSCT) to treat non-malignant diseases, particularly sickle cell disease (SCD). The key objectives are to: 1) Evaluate novel stem cell mobilization regimens combining VLA-4 and CXCR4 inhibition to generate...

The Children's Hospital Corporation, doing business as Boston Children's Hospital, received a $2,000 Project Grant award from the National Institutes of Health's John E. Fogarty International Center (CFDA 93.989 - International Research and Research Training) to study ATP1A3-related disorders in Brazil. The key goals of this 2-year project are to: Establish a large patient cohort in Brazil to study the genotype-phenotype correlation and natural history of ATP1A3-related disorders, which...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $234,000 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Colorado-Denver to engineer and test "hemostatic red blood cells" (T-RBCs) for the treatment of acute non-compressible hemorrhage. The key objectives are to: 1) engineer T-RBCs that bind to collagen and fibrin to enhance clot formation and stability, 2) perform in vitro testing of the T-RBCs' hemostatic properties, and 3)...

This federal Project Grant award of $1,020,000 from the U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA) HIV/AIDS Bureau under the Special Projects of National Significance (SPNS) program (CFDA 93.928) aims to improve HIV care and treatment for racial and ethnic minority populations in the Atlanta, Georgia metropolitan area. The "CASHA: Collaborative Approach to Syndemic Health in Atlanta" project, led by Positive Impact Health...

This Project Grant award of $470,553 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to Emory University aims to elucidate the genetic factors regulating the immune response to factor VIII (FVIII) in patients with hemophilia A. The research will use a genetically diverse mouse model to identify key genetic traits that influence the development of anti-FVIII antibodies, which can render FVIII replacement therapy...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,371,242 to The University of Texas Rio Grande Valley to conduct research on identifying genetic and environmental factors underlying the high incidence of factor VIII inhibitors in hemophilia A patients of Mexican ancestry. The 4-year project aims to: 1) enroll and characterize a cohort of 200 severe hemophilia A patients, 2) elucidate the genetic basis of...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $254,604 to Dana-Farber Cancer Institute, Inc. to develop and implement a community-based collaborative care model to deliver a resilience-focused intervention for adolescents and young adults with non-malignant blood disorders, such as sickle cell disease. The 5-year project aims to (1) assess the feasibility and acceptability of the...

This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) will support the development and testing of a transitional care intervention to improve communication and quality of life outcomes for individuals with aphasia, a chronic language impairment. The $100,000 award to The Spaulding Rehabilitation Hospital Corporation, a non-profit hospital and academic medical center in Massachusetts, will fund a 5-year project to (1)...